Does CBD affect glutamate levels in the brains of people with early psychosis?
A small double-blind crossover trial found that a single 600 mg dose of CBD significantly increased hippocampal glutamate levels in psychosis patients, with a corresponding decrease in symptom severity.
Quick Facts
What This Study Found
Compared to placebo, CBD produced a significant increase in hippocampal glutamate (p=0.035) and a significantly greater decrease in symptom severity on the PANSS scale (p=0.032). A significant negative correlation existed between post-treatment symptom scores and glutamate levels (p=0.047), suggesting the glutamate increase may be linked to symptom improvement.
Key Numbers
13 patients; 600 mg CBD single dose; hippocampal glutamate increase p=0.035; symptom severity decrease p=0.032; glutamate-symptom correlation p=0.047
How They Did This
Double-blind, randomized, placebo-controlled, repeated-measures, within-subject crossover design. 13 patients with psychosis received a single oral dose of CBD (600 mg) or placebo on separate days. Hippocampal glutamate measured via proton magnetic resonance spectroscopy.
Why This Research Matters
Understanding how CBD might work as an antipsychotic is crucial for developing new treatments. This study provides the first evidence linking CBD's effects on glutamate signaling to symptom improvement in psychosis patients.
The Bigger Picture
Most current antipsychotics target dopamine pathways. If CBD works through glutamate modulation, it represents a fundamentally different mechanism that could benefit patients who do not respond to existing treatments.
What This Study Doesn't Tell Us
Very small sample (13 patients). Single-dose design cannot show whether effects persist with repeated use. Within-subject crossover reduces confounders but limits generalizability.
Questions This Raises
- ?Does repeated CBD dosing produce sustained changes in glutamate signaling?
- ?Would this mechanism apply across different stages of psychosis?
- ?How does this glutamate effect interact with conventional antipsychotic treatment?
Trust & Context
- Key Stat:
- 600 mg CBD; p=0.035 glutamate increase
- Evidence Grade:
- Double-blind crossover RCT but very small sample (n=13) and single-dose design.
- Study Age:
- Published in 2021; part of an ongoing research program on CBD in psychosis.
- Original Title:
- Cannabidiol modulation of hippocampal glutamate in early psychosis.
- Published In:
- Journal of psychopharmacology (Oxford, England), 35(7), 814-822 (2021)
- Authors:
- O'Neill, Aisling(5), Annibale, Luciano(3), Blest-Hopley, Grace(10), Wilson, Robin, Giampietro, Vincent, Bhattacharyya, Sagnik
- Database ID:
- RTHC-03390
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
What is glutamate and why does it matter in psychosis?
Glutamate is the brain's main excitatory neurotransmitter. Dysfunction in glutamate signaling has been linked to psychosis, and this study suggests CBD may influence symptoms by modulating glutamate levels in the hippocampus.
Is CBD an antipsychotic?
CBD has shown antipsychotic-like effects in several studies, but it is not approved as an antipsychotic. This study provides evidence for one possible mechanism: modulating glutamate signaling in the hippocampus.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03390APA
O'Neill, Aisling; Annibale, Luciano; Blest-Hopley, Grace; Wilson, Robin; Giampietro, Vincent; Bhattacharyya, Sagnik. (2021). Cannabidiol modulation of hippocampal glutamate in early psychosis.. Journal of psychopharmacology (Oxford, England), 35(7), 814-822. https://doi.org/10.1177/02698811211001107
MLA
O'Neill, Aisling, et al. "Cannabidiol modulation of hippocampal glutamate in early psychosis.." Journal of psychopharmacology (Oxford, 2021. https://doi.org/10.1177/02698811211001107
RethinkTHC
RethinkTHC Research Database. "Cannabidiol modulation of hippocampal glutamate in early psy..." RTHC-03390. Retrieved from https://rethinkthc.com/research/o-neill-2021-cannabidiol-modulation-of-hippocampal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.